One: The United States will give up COVID-19's vaccine intellectual property patent. The Biden administration announced that the United States would give up the intellectual property patent of COVID-19 vaccine, and said? The COVID-19 epidemic is a global public health crisis, which requires extraordinary measures. The US government is well aware of the necessity of intellectual property rights, but in order to end this epidemic, it should popularize safe and effective vaccines as soon as possible. The U.S. government will continue to strengthen cooperation with the private sector and all possible partners, expand the manufacture and sale of vaccines, and strive to increase the raw materials needed to produce these vaccines? . After this decision was announced in the United States, it immediately caused extensive discussion and controversy all over the world. Supporters believe that this will increase the global COVID-19 vaccine production capacity and is of great significance to the global anti-epidemic campaign; Opponents believe that giving up intellectual property patents will seriously affect the economic returns that vaccine research and development enterprises should have, and their market share will also shrink, thus affecting their stock prices.
Second, the impact of the United States giving up COVID-19's vaccine patent. The United States announced that it would give up COVID-19's patent on vaccine intellectual property rights, which had both positive and negative effects. The positive effect is that only a few countries in the world can develop and produce COVID-19 vaccine. Facing more than 200 countries with a population of more than 7.5 billion, COVID-19's vaccine production capacity in these countries is far from being satisfied. After the United States abandons the intellectual property patent of COVID-19 vaccine, more pharmaceutical companies can join the ranks of vaccine production, which can increase COVID-19's vaccine production capacity to a certain extent and let more people in the world get COVID-19 vaccine, which will play a positive role in the global fight against the COVID-19 epidemic. The negative impact is that when the United States abandons the intellectual property patent of COVID-19 vaccine, the enterprises that originally developed COVID-19 vaccine will face more competitors, and these enterprises will not be able to collect considerable patent license fees, and their market share will also be affected, thus reducing the expected profit value of the market to these enterprises and directly affecting their stock prices. In addition, when more companies join the vaccine production in COVID-19, it is possible to produce low-quality vaccines in COVID-19 to seize the market. At the same time, the original vaccine manufacturers don't have enough funds and energy to develop new vaccines, which will have a certain negative impact on COVID-19's global vaccine industry.
Three. Event evaluation Although the United States will give up the intellectual property patent of COVID-19 vaccine, the difficulty in producing COVID-19 vaccine is that only a few pharmaceutical companies with certain qualifications and capabilities can meet the production requirements of COVID-19 vaccine, so it is impossible to effectively solve the shortage of COVID-19 vaccine in a short time. With regard to COVID-19's vaccine intellectual property rights patent, since the COVID-19 epidemic is the enemy of all mankind, COVID-19 vaccine has surpassed the value orientation of ordinary products. At this special moment, COVID-19 vaccine has become the key to determine whether human beings can overcome the COVID-19 epidemic as soon as possible. It is suggested that before the global COVID-19 epidemic is effectively controlled, the intellectual property patent of the new crown vaccine should be set as a free period. After the global COVID-19 epidemic has been effectively controlled, these original vaccine manufacturers can restore the patents of COVID-19 vaccine knowledge products, which can not only guarantee their due economic returns, but also avoid the emergence of shoddy COVID-19 vaccines in the market.